07/08/2021
In NCCN guidelines for the management of Node-positive Early-stage Breast Cancer, the Oncotype DX® Test
has been recognized as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit.
Oncotype DX Breast Recurrence Score® test has been recognized as the only test that can be used for prediction of chemotherapy benefit in early-stage postmenopausal breast cancer patients with 1-3 positive axillary lymph nodes, including micrometastases, by the National Comprehensive Cancer Network (NCCN) in its updated guidelines for breast cancer.
The Oncotype DX® test is now the only test classified as “preferred” with the highest level of evidence for node-positive and postmenopausal node-positive patients.
Following are the treatment suggestions by 21 genes Oncotype Dx Premenopausal patients with (1-3 positive nodes)
Postmenopausal Patients with pT1-3, HR-positive, HER-2 Negative Tumors with recurrence score (RS)
